Silver Book Fact

Survival Rates of SAS Patients with and without SAVR

Patients with severe aortic stenosis (SAS) ages 80+ who underwent surgical aortic valve replacement (SAVR) have 1-year, 2-year, and 5-year survival rates of 87%, 78%, and 68% respectively — compared with 52%, 40%, and 22% for those patients who did not have surgery.

Varadarajan P, Kapoor N, Bansal R, Pai R. Survival in Elderly Patients with Severe Aortic Stenosis is Dramatically Improved by Aortic Valve Replacement: Results from a cohort of 233 patients aged ≥ 80 years. Eur J Cardiothorac Surg. 2006; 30(5): 722-7. https://academic.oup.com/ejcts/article/30/5/722/361607/Survival-in-elderly-patients-with-severe-aortic

Reference

Title
Survival in Elderly Patients with Severe Aortic Stenosis is Dramatically Improved by Aortic Valve Replacement: Results from a cohort of 233 patients aged ≥ 80 years
Publication
Eur J Cardiothorac Surg
Publication Date
2006
Authors
Varadarajan P, Kapoor N, Bansal R, Pai R
Volume & Issue
Volume 30, Issue 5
Pages
722-7
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • TAVR v. SAVR in Intermediate-Risk SAS Patients
    At 1-year, severe aortic stenosis (SAS) patients with intermediate surgical mortality risk who underwent transcatheter aortic valve replacement (TAVR), had all-cause mortality rates of 7.4% (compared to 13% for surgical…  
  • Improvements in QoL from TAVR in SAS patients
    Symptomatic aortic stenosis (SAS) patients who underwent transcatheter aortic valve replacement (TAVR) experienced quality of life (QoL) improvements from 5.3 at baseline (10 point scale with 10=best imaginable health state)…  
  • Undertreatment of patients with sSAS
    AS is often undertreated — one study found that 56% of severe symptomatic aortic stenosis (sSAS) patients referred to a cardiothoracic surgeon were not operated on.  
  • TAVR improves quality of life in SAS patients
     
  • Cost-effectiveness of SAVR
    The cost-effectiveness ratio for surgical aortic valve replacement (SAVR), compared to no surgery, was estimated at $13,528 per quality-adjusted life year (QALY) (~$17,225 in 2017 dollars).